TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

RAD Increases Ownership in Radiopharm Ventures to 87.5%

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Not Specified
RAD Increases Ownership in Radiopharm Ventures to 87.5%

Radiopharm Theranostics increased its ownership stake in Radiopharm Ventures (joint venture with MD Anderson Cancer Center) from 75% to 87.5%. The leading candidate Betabart, a B7H3-targeting monoclonal antibody, received FDA IND clearance and is expected to dose the first patient in Q1 2026 in a Phase I trial for solid tumors. Two additional preclinical assets show early positive results with final candidate selection planned for 2026.

Insights
SHOP   neutral

Mentioned in context of beta-testing Managed Markets flow without detailed performance information


RADX   positive

Company increased ownership stake in promising joint venture, lead candidate received FDA IND clearance, first-in-human trial expected to begin Q1 2026, and additional preclinical candidates showing positive results. These developments indicate strong pipeline progress and confidence in the program's potential.